NRx Pharmaceuticals (NASDAQ:NRXP) Releases Earnings Results, Beats Estimates By $0.01 EPS

NRx Pharmaceuticals (NASDAQ:NRXP) issued its earnings results on Friday. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01, FiscalAI reports. The business had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $25.57 million.

NRx Pharmaceuticals Trading Up 2.2%

Shares of NASDAQ:NRXP traded up $0.07 during midday trading on Friday, hitting $3.28. 2,216,622 shares of the stock were exchanged, compared to its average volume of 1,224,002. The company has a 50 day moving average price of $2.43 and a 200-day moving average price of $2.32. NRx Pharmaceuticals has a twelve month low of $1.62 and a twelve month high of $3.84. The stock has a market cap of $108.47 million, a P/E ratio of -2.36 and a beta of 2.02.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Anson Funds Management LP increased its stake in shares of NRx Pharmaceuticals by 50.3% during the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock worth $8,249,000 after purchasing an additional 1,018,853 shares in the last quarter. State Street Corp boosted its stake in shares of NRx Pharmaceuticals by 14.0% during the fourth quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after acquiring an additional 10,700 shares during the last quarter. Commonwealth Equity Services LLC acquired a new stake in shares of NRx Pharmaceuticals during the fourth quarter valued at $994,000. Geode Capital Management LLC boosted its stake in shares of NRx Pharmaceuticals by 17.8% during the fourth quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock valued at $593,000 after acquiring an additional 33,004 shares during the last quarter. Finally, Two Sigma Investments LP boosted its stake in shares of NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after acquiring an additional 20,880 shares during the last quarter. 4.27% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on NRXP. Zacks Research raised NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. HC Wainwright reiterated a “buy” rating and issued a $45.00 price objective on shares of NRx Pharmaceuticals in a research note on Monday, April 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Friday, May 8th. D. Boral Capital reiterated a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. Finally, BTIG Research reissued a “buy” rating and set a $25.00 price target on shares of NRx Pharmaceuticals in a research note on Tuesday, March 24th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, NRx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.25.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.